News Related to Interleukin-1 Receptor Accessory Protein

Related coverage linked through entity extraction aliases.

IL1RAP-Targeted ADC Shows Preclinical Promise in Ewing Sarcoma and Fusion-Driven Cancers

Jul 12, 2026

A new antibody-drug conjugate targeting IL1RAP has shown potent preclinical activity against Ewing sarcoma and other fusion-driven cancers, with minimal off-target toxicity. Researchers at UBC report tumor eradication and reduced metastasis, with clinical trials being planned.

Cantargia Reports 2025 Financials, Secures Financing to Accelerate Nadunolimab Development

Jun 21, 2026

Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.